Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine

The roadmap concept suggests the use of on-treatment HBV DNA to guide treatment strategy of chronic hepatitis B patients treated by telbivudine. Our aim was to validate the roadmap approach of entecavir switch therapy in patients with incomplete response to telbivudine. Consecutive chronic hepatitis...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2013-01, Vol.18 (5), p.671-679
Main Authors: OI-SHAN LO, Angeline, WAI-SUN WONG, Vincent, WONG, Grace Lai-Hung, CHAN, Hoi-Yun, CHEUNG, Christina Man-Tung, CHAN, Henry Lik-Yuen
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Drug Resistance, Viral
Drug Substitution
Female
Follow-Up Studies
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Male
Medical sciences
Middle Aged
Mutation
Pharmacology. Drug treatments
Retrospective Studies
Risk Factors
Thymidine - analogs & derivatives
Thymidine - therapeutic use
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The roadmap concept suggests the use of on-treatment HBV DNA to guide treatment strategy of chronic hepatitis B patients treated by telbivudine. Our aim was to validate the roadmap approach of entecavir switch therapy in patients with incomplete response to telbivudine. Consecutive chronic hepatitis B patients on telbivudine monotherapy were studied. Incomplete virological response was defined as detectable HBV DNA after 6-12 months of treatment. Maintained virological response was defined as undetectable HBV DNA until the last follow-up. Among the 79 patients on telbivudine, 39 (49%) had undetectable HBV DNA after 6-12 months of telbivudine treatment and 40 (51%) had incomplete virological response. In total, 33 incomplete responders switched to entecavir at 11 months (6-23), and 26 (79%) achieved maintained virological response after 25 months (4-46). Low HBV DNA level before switch therapy was the independent factor associated with maintained virological response to entecavir (P=0.01). A total of 24 of 25 (96%) patients with HBV DNA
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP2526